Concepedia

Publication | Open Access

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

DOIFull Paper Access

220

Citations

22

References

2014

Year

S.-H.I. Ou, Pasi A. Jänne, Cynthia Huang Bartlett, Yiyun Tang, D.-W. Kim, Gregory A. Otterson, Lucio Crinò, Paulina Selaru, D. P. Cohen, Jeffrey W. Clark,
Annals of Oncology

Abstract

Patients who continued CBPD were more likely to have good ECOG PS (0/1) at the time of PD. Continuing ALK inhibition with crizotinib after PD may provide survival benefit to patients with advanced ALK-positive NSCLC.

References

YearCitations

Page 1